MarginsXMarginsX
Home › Markets › Health Care › DERM

Journey Medical Corporation (DERM)

DERM trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$3.70
-14.55% on the day
Market cap
$104.5M
Micro cap
Revenue · 2025
$61.9M
+10.2% on 2024
Net income · 2025
-$11.4M
-18.5% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1867066/000110465926034629/0001104659-26-034629-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerDERM on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2021
SEC CIK0001867066
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$61.9M
Net income-$11.4M
Operating income-$8.2M
Net margin-18.5%
Operating margin-13.2%
Revenue growth+10.2%
Cash$24.1M
Total assets$94.6M
P/E (computed)Net income was not positive
P/S (computed)1.7×

Warning signs

Cash runway
31.3 months
$22.3M cash at September 30, 2026
Share count, 1 year
+4.0%
2025-10-31 to 2026-11-12
Going-concern doubt
Yes
10-Q filed November 12, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"However, as a result of recurring and historical losses, substantial doubt exists about the Company's ability to continue as a going concern for a period of at least twelve months from the date of issuance of these financial statements."
10-Q 2026-11-12
Cash and burn$22.3M cash; operating cash flow -$2.1M a quarter.Report 2026-09-30
Shares outstanding28,230,645 (2026-11-12); 27,135,905 a year earlier.Cover page 2026-11-12
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-01-15
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKPMG LLP, Short Hills, New Jersey, United StatesPCAOB Form AP 2026-04-28
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$19.0M-$1.3M-$3.4M$22.3M$25.6M$69.5M10-Q 2026-11-12
Q2 2026
2026-06-30
$18.5M-$312K-$1.7M$25.6M$25.5M$68.2M10-Q 2026-08-12
Q1 2026
2026-03-31
$16.0M-$2.2M$2.9M$27.2M$25.4M$64.7M10-Q 2026-05-13
Q4 2025
2025-12-31
$16.1M-$1.2M-$6.3M$24.1M$25.3M$61.9M10-K 2026-03-26
Q3 2025
2025-09-30
$17.6M-$2.3M-$2.4M$24.9M$25.2M$59.4M10-Q 2026-11-12
Q2 2025
2025-06-30
$15.0M-$3.8M-$942K$20.3M$25.1M$56.4M10-Q 2026-08-12
Q1 2025
2025-03-31
$13.1M-$4.1M-$2.8M$21.1M$25.0M$56.2M10-Q 2026-05-13
Q4 2024
2024-12-31
$13.6M$1.5M$2.2M$20.3M$24.9M$56.1M10-K 2026-03-26

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32026-01-23
Latest annual report10-K2026-03-26
Latest quarterly / interim10-Q2026-11-12
Latest current report
FORM 8-K
8-K2026-11-12
Latest proxyDEFA14A2026-04-30

Source: SEC EDGAR submissions feed, 231 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-3.1%
1 month-23.8%
3 months-34.9%
Year to date-43.8%
1 year-43.7%
From 52-week high-53.2%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
CLLSCellectis S.A.$1.04-11.86%$104.5M
ORGOOrganogenesis Holdings Inc.$0.8031-0.86%$104.2M
ADAGAdagene Inc.$1.60-6.43%$105.7M
UNCYUnicycive Therapeutics Inc.$3.70+4.23%$103.1M
CUECue Biopharma Inc.$14.10-12.53%$102.4M
OGIOrganigram Global Inc. Common Shares$0.7240-12.62%$102.2M
BGMBGM Group Ltd.$8.01+1.71%$107.0M
FHTXFoghorn Therapeutics Inc.$1.79-13.53%$107.3M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier